Kerri Fitzgerald
Articles by Kerri Fitzgerald
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
The combination of decitabine/cedazuridine, venetoclax, and an IDH1 inhibitor was effective in treating IDH-mutated AML.
Ivosidenib and azacitidine led to deep and durable remissions associated with clearance of IDH1-mutated newly diagnosed AML.
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
670 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.